(MedPage Today) — More lawsuits are alleging that patients are not being sufficiently warned of certain severe injuries associated with GLP-1 receptor agonists. (USA Today)
Meanwhile, the U.K.’s Medicines and Healthcare Products Regulatory Agency…

In the world of obesity research, the arrival of GLP-1 drugs like Ozempic feels seismic. At a recent conference, Martin Binks, a leader in obesity research, found himself marveling with a colleague: “Can you believe we finally reached this moment, that we lived long enough to see this?”

Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.

Nearly three months after winning a contentious bid to buy obesity drugmaker Metsera Inc. for $10 billion, Pfizer Inc. reported its first statistically significant top-line data of the acquired lead, ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, showing a mean placebo-adjusted weight loss of up to 12.3% at 28 weeks, as well as competitive tolerability.

Researchers at Steno Diabetes Center Copenhagen reported that starting a GLP-1 receptor agonist (GLP-1RA) coincided with slightly healthier supermarket purchases. Grocery purchases from GLP-1RA users in Denmark contained modestly fewer calories and sugars and slightly more protein per 100 g of food after treatment began than before.

TUESDAY, Feb. 3, 2026 — Postmenopausal women who used hormone therapy lost significantly more weight while taking tirzepatide than women only taking tirzepatide, according to a study published online Jan. 22 in The Lancet Obstetrics, Gynaecology…

While CagriSema bested Novo Nordisk’s Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma’s 25% weight loss goal.

Pfizer said Tuesday that the monthly injection that was one of the cornerstones of its $10 billion buyout of Metsera allowed obesity patients to lose up to 10.5% of their weight, on …

(MedPage Today) — Oral semaglutide (Rybelsus) protected against heart failure events in type 2 diabetes patients with a history of heart failure and either atherosclerotic cardiovascular disease, chronic kidney disease, or both, according to findings…

Emerging evidence suggests that oral semaglutide may reduce the risk of heart failure–related events in people with type 2 diabetes. JasonDoiy/Getty Images

Oral semaglutide may reduce heart failure events in high-risk individuals with type 2 diabetes.

The benefit appeared strongest among those with a common but hard-to-treat form of heart failure. 

Novo Nordisk’s next-gen metabolic drug CagriSema performed better than the blockbuster semaglutide at reducing blood sugar and weight in patients with type 2 diabetes.

That was the topline result from the latest Phase 3 readout …

Semaglutide erased the constant mental chatter about food that had ruled her life, but along with it went her awareness of basic needs.

The Food and Drug Administration (FDA) recently approved a tablet version of the GLP-1 drug Wegovy for weight loss. Image courtesy of Novo Nordisk

Research shows that people who stop taking GLP-1 medications regain weight within 2 years.

A new study has found that people regain weight within 2 years of stopping a GLP-1 drug.

Metabolic improvements also tend to fade within that time, researchers found.

A combination of hormone therapy and the GLP-1 drug tirzepatide may promote weight loss in postmenopausal females. Image Credit: Mauro Grigollo/Stocksy

A new study found that postmenopausal females who use hormone therapy in combination with tirzepatide experience greater weight loss compared to those who don’t. 

Sciwind Biosciences Co. Ltd. said Jan. 30 it won Chinese approval for self-developed glucagon-like peptide-1 (GLP-1) receptor agonist, ecnoglutide (Xianyida), to treat adults with type 2 diabetes.

EU regulators have refused to greenlight Eli Lilly’s weight loss drug Mounjaro as a treatment for a type of heart failure, while giving the go-ahead for Novo Nordisk’s semaglutide in liver disease.

Lilly failed to …

Eli Lilly has budgeted $3.5 billion for a new weight loss injectable and device factory in Lehigh Valley, PA, which will manufacture its next-gen obesity drug retatrutide.

The factory will also produce other weight loss …

(MedPage Today) — Note that some links may require registration or subscription.
The United Kingdom’s Medicines and Healthcare Products Regulatory Agency strengthened its warnings on GLP-1 receptor agonists and dual GLP-1/GIP agonists to include…

(MedPage Today) — GLP-1 receptor agonist use was tied to a lower risk of recurrent major adverse limb events (MALEs) in people with diabetes compared with another drug class, a retrospective Taiwanese study showed.
Among 17,288 patients, new…

A renowned physician-scientist says treatment is not one-size-fits-all.

THURSDAY, Jan. 29, 2026 — Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with reduced postoperative revision following functional endoscopic sinus surgery (FESS) for up to five years among patients with chronic…

(MedPage Today) — Note that some links may require registration or subscription.
“Night owls” may be at higher risk of cardiovascular disease, but it mostly comes down to their overall health behaviors, according to a U.K. Biobank cohort study…

(MedPage Today) — Use of tirzepatide (Mounjaro, Zepbound) was tied to a reduced incidence of new or progressive diabetic retinopathy and fewer complications in patients with diabetes and overweight/obesity, a retrospective study suggested.
In…

Ozempic, Mounjaro, and Zepbound can drive impressive weight loss, but stopping them is often followed by rapid weight regain. Researchers found that people regain weight faster after quitting these drugs than after diet and exercise alone. Improvements in heart health and diabetes risk also tend to reverse within a few years. The results suggest long-term success may require more than medication alone.

(MedPage Today) — Tirzepatide (Mounjaro, Zepbound) users should never share KwikPens due to risk for transmission of blood-borne pathogens, the FDA warned in an updated label.
GLP-1 medications for weight loss accounted for more than 7% of all…

Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.

(MedPage Today) — Postmenopausal women on the GLP-1 medication tirzepatide (Zepbound) for obesity lost more weight if they were also using menopause hormone therapy, a retrospective cohort study indicated.
Among 120 women with overweight or obesity…

According to doctors, making a misstep is easier than you may think.

South San Francisco, CA — January 26, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP…

I’m a candidate for the meds, but they’re not for me—at least for now.

Novo, Regeneron and Pfizer all landed weight loss deals with China-based companies last year.

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause.

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

(MedPage Today) — Meals and snacks with “GLP-1 Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans try obesity drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) to lose weight…